Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01678794 · ClinicalTrials.gov registry record · Phase 1
CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01678794: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01678794 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01678794, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and cGMP pathway. The belief is that the chronic AT1 receptor blockade in subjects with compensated CHF and renal dysfunction will improve renal function with increased sodium excretion, glomerular filtration rate and effective renal plasma flow and renal function reserve as compared to the response of placebo-treated subjects.
Interventions
- DRUG Placebo
- DRUG Candesartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-06-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01678794
The ClinicalTrials.gov registry entry for NCT01678794 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01678794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01678794 about?
NCT01678794 is a clinical study titled "CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function". To advance our understanding of the mechanisms of human cardiorenal syndrome with emphasis upon the interaction of diuretic therapy and the renal-angiotensin-aldosterone -system and cGMP pathway. The belief is that the chronic AT1 receptor blockade in subjects with compensated CHF and renal dysfunc...
What is the current status of trial NCT01678794?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2012-02. Estimated completion is 2016-06-29.
What interventions are being tested in trial NCT01678794?
The interventions under investigation include: Placebo (DRUG), Candesartan (DRUG).
Who is sponsoring clinical trial NCT01678794?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.